Introduction
============

Gastric cancer (GC) is a common cancer and the second leading cause of cancer mortalities worldwide ([@b1-ol-0-0-10122]). GC is a multifactorial disease that involves oncogene activation and tumor suppressor gene inactivation ([@b2-ol-0-0-10122]). The majority of patients are at stage III and IV when diagnosed and the 5-year survival rate is as low as 5% ([@b3-ol-0-0-10122]). Gene mutations may affect the proliferation, invasion and metastasis of cancer cells and the prognosis of patients with GC ([@b4-ol-0-0-10122]--[@b6-ol-0-0-10122]), and elucidating the pathways involved in these mutations may improve the diagnosis, treatment and prognosis of GC.

Radiotherapy serves an important role in the treatment of various types of cancer and the National Comprehensive Cancer Network guidelines recommend adjuvant chemoradiotherapy as a standard treatment for postoperative patients with GC ([@b7-ol-0-0-10122]). Advances in radiotherapy protocols and precise radiotherapy techniques have improved the efficacy of radiotherapy ([@b8-ol-0-0-10122]). However, the efficacy can vary for certain patients with similar pathologies and radiotherapy regimens, and radiotherapy is highly toxic to normal tissues ([@b9-ol-0-0-10122]). Therefore, the identification of genes involved in radiation sensitivity may improve patient outcomes.

In the context of radiation therapy, E3 ubiquitin ligase has been revealed to sensitize tumor cells to radiation, and is thought to be involved in the regulation of apoptosis, the cell cycle and DNA damage repair ([@b10-ol-0-0-10122],[@b11-ol-0-0-10122]). Tripartite motif containing 36 (TRIM36) has unique E3 ubiquitin ligase activity and serves an important role in transcriptional regulation, cell proliferation, apoptosis and regulation of the p53 signaling pathway ([@b12-ol-0-0-10122],[@b13-ol-0-0-10122]). p53 inactivation may significantly modulate the sensitivity of tumor cells to radiation and chemotherapeutic drugs ([@b14-ol-0-0-10122],[@b15-ol-0-0-10122]). Conventional radiotherapy may cause DNA damage and activation of the DNA damage response, resulting in the expression of the p53 gene ([@b16-ol-0-0-10122],[@b17-ol-0-0-10122]). DNA repair is a regulatory mechanism to overcome cell damage and avoid genomic instability ([@b18-ol-0-0-10122]). TRIM36 serves a key role in regulating the stability and function of the p53 protein and may therefore affect the efficacy of radiotherapy ([@b19-ol-0-0-10122]).

In the present study, The Cancer Genome Atlas (TCGA; [cancergenome.nih.gov](cancergenome.nih.gov); updated September 2017) database was used to summarize the clinicopathological features that affect the prognosis of patients with GC. TRIM36 mRNA expression levels were used to divide the patients into different groups and cross-validation was performed to analyze the association between TRIM36 status and the prognosis of patients with GC receiving radiotherapy.

Materials and methods
=====================

### Clinicopathological and RNA-sequencing data

Clinical information and TRIM36 mRNA sequencing data of patients with GC were downloaded from TCGA using the TCGA-Assembler tool on R software (version 3.4.0; [www.r-project.org](www.r-project.org)). The data disposal process was as follows: The clinical data were merged to obtain the patient survival information, patients without a survival time or survival outcome were excluded and the data were subsequently merged with other clinical data to obtain a complete clinical document; duplicated individuals were removed; the final 371 patients were included in the statistical analysis. Clinicopathological data included survival time, sex, age at illness and mortality, histology type, Tumor-Node-Metastasis (TNM) stage and grade, residual tumor and chemotherapy and radiotherapy received.

### Radiosensitivity gene TRIM36 groups

The 371 samples were divided into the test group and the validation group. The test group and the validation group were further divided into high-expression and low-expression subgroups according to the median level of TRIM36 in the test group. Each group of stage III and IV patients was combined to investigate the association between TRIM36 expression status and radiosensitivity.

### Statistical analysis

The digital database of clinicopathological information and TRIM36 expression status of the 371 patients was established using R software. The TRIM36 status below the median was defined as '0' and TRIM36 at or above the median was defined as '1'. The association between TRIM36 expression and clinicopathology was examined using the Chi-squared test. Kaplan-Meier survival analysis was performed to determine the radiotherapy factor for OS and a log-rank test was used to compare the radiotherapy and non-radiotherapy groups. Univariate Cox proportional hazards regression was used to evaluate the effect of a single factor. To control confounding variables, multivariate Cox proportional hazards regression models were generated with the significant clinicopathological factors. Statistical analyses were performed using the packages 'survival' and 'rms' packages in R software. P\<0.05 was considered to indicate a statistically significant difference. All of the statistical analyses were performed twice to ensure accuracy.

Results
=======

### Patients and tumor characteristics

The mean patient age was 65 years (range, 30--90 years). Univariate analysis revealed that TNM-stage (P=0.001), T-stage (P=0.007), N-stage (P=0.001), tumor grade (P=0.001), residual tumor (P=0.001), targeted therapy (P=0.018) and radiotherapy (P=0.001) were statistically significant for the overall survival (OS) rate in all patients. Multivariate analysis revealed that residual tumor (P=0.003) and radiotherapy (P=0.005) served important roles in GC outcome in all patients. TRIM36 expression status was not associated with the OS rate in the three groups ([Table I](#tI-ol-0-0-10122){ref-type="table"}).

### Association between TRIM36 expression and clinicopathological parameters

Analysis of the association between TRIM36 status and other clinical factors was performed using the Chi-squared test ([Table II](#tII-ol-0-0-10122){ref-type="table"}). The expression status of TRIM36 was independent of histology (P=0.951), TNM-stage (P=0.750), distant metastasis (P=0.723) and tumor grade (P=0.811). The expression of genes associated with prognosis in patients with a tumor is often associated with clinicopathological factors ([@b20-ol-0-0-10122]--[@b22-ol-0-0-10122]). However, in the current study TRIM36 expression status was not associated with clinical and pathological factors.

### Analysis of TRIM36 gene expression in the test group

The total number of samples was divided into test and validation groups. Survival rate analysis was performed in the test group. Based on the median value of TRIM36 expression in the test group, the group was divided into high- and low-expression subgroups. In the high TRIM36 expression subgroup, the OS rate of patients treated with radiotherapy was significantly increased compared with patients who did not receive radiotherapy ([Fig. 1A](#f1-ol-0-0-10122){ref-type="fig"}). The OS rate was not associated with whether patients had received radiotherapy in the low expression subgroup ([Fig. 1B](#f1-ol-0-0-10122){ref-type="fig"}).

Multivariate Cox proportional hazard regression models for the test group of patients were generated according to the following clinicopathological characteristics: Sex, age, histological type, TNM-stage, tumor grade, residual tumor, positive lymph nodes and targeted therapy. The multivariate Cox proportional hazard regression analysis ([Table III](#tIII-ol-0-0-10122){ref-type="table"}) revealed that while the OS rate of patients with GC receiving radiotherapy in the high-expression subgroup was increased \[hazard ratio (HR), 0.095; 95% confidence interval (CI), 0.012--0.748; P=0.025\], there was no difference in the OS rate in the low-expression subgroup (P=0.643).

### Analysis of TRIM36 expression in the validation group

The same statistical analysis as described for the test group was performed in the validation group. The results suggested that radiotherapy was associated with increased OS in the high TRIM36 expression subgroup ([Fig. 1C](#f1-ol-0-0-10122){ref-type="fig"}). No difference in the OS rate between patients with GC receiving radiotherapy and those not receiving radiotherapy was observed in the low TRIM36 expression subgroup ([Fig. 1D](#f1-ol-0-0-10122){ref-type="fig"}). Multivariate Cox proportional hazard regression analysis ([Table III](#tIII-ol-0-0-10122){ref-type="table"}) revealed that patients with GC that received radiotherapy displayed improved OS rates when compared with patients with GC that did not receive radiotherapy in the high expression group (HR, 0.075; 95% CI, 0.020--0.276; P\<0.001). However, in the low expression subgroup, the OS rate of patients with GC that received radiotherapy was not different compared with patients with GC that did not receive radiotherapy (P=0.661).

### Analysis of TRIM36 expression in all patients

The 371 samples were divided into high and low expression subgroups according to the median expression level of TRIM36 in the test group. Univariate analysis revealed that patients with high expression that received radiotherapy had a lower risk of mortality ([Fig. 1E](#f1-ol-0-0-10122){ref-type="fig"}) compared with those that did not receive radiotherapy, and that radiotherapy did not affect mortality in the low expression subgroup ([Fig. 1F](#f1-ol-0-0-10122){ref-type="fig"}). Multivariate analysis revealed that there was no difference in OS rates in patients that received radiotherapy compared with those that did not receive radiotherapy in the low expression subgroup (P=0.658; [Table III](#tIII-ol-0-0-10122){ref-type="table"}). However, the OS rate of patients that received radiotherapy was significantly improved when compared with those that did not receive chemotherapy in the high expression subgroup (HR, 0.094; 95% CI, 0.030--0.296; P\<0.001). Univariate and multivariate analysis revealed that radiotherapy significantly increased the OS rate of patients with high expression of TRIM36 compared with patients with low expression.

### Association between tumor stage, TRIM36 status, radiotherapy and OS rate

Patients with TNM-stage I, II, III and IV cancer were analyzed separately. Patients with stage III and IV cancer were grouped together, due to the small sample size of patients with stage IV cancer. According to the aforementioned statistical methods, for each subgroup analysis, survival analysis revealed that patients presenting with stage III/IV, a high TRIM36 expression level and had received radiotherapy had significantly increased OS rates compared with patients with a high expression level that did not receive radiotherapy. The survival curves of the test group, the validation group and the total sample group are presented in [Fig. 2A, C and E](#f2-ol-0-0-10122){ref-type="fig"}, respectively. In the test, validation and total sample groups, there was no difference in the OS rates of patients with stage III/IV that had low TRIM36 expression and had received radiotherapy compared to those that did not receive radiotherapy ([Fig. 2B, D and F](#f2-ol-0-0-10122){ref-type="fig"}).

Discussion
==========

Personalized radiotherapy an important factor in the development of radiology ([@b23-ol-0-0-10122]). In the present study, the OS rate of patients with high TRIM36 expression receiving radiotherapy was increased compared with patients with low TRIM36 expression receiving radiotherapy. This suggested that the TRIM36 gene may be a useful prognostic biomarker for patients with GC receiving radiotherapy. To the best of the authors\' knowledge, the current study is the first to establish an association between radiosensitivity and TRIM36 expression status in patients with GC.

The American Joint Committee on Cancer staging system is a widely used clinical prognostic indicator for malignant tumors ([@b24-ol-0-0-10122]). In the current study, an association between high TRIM36 expression and sensitivity to radiotherapy was established. The majority of patients receiving postoperative radiotherapy for GC were patients with TNM-stage III and IV. To avoid interference of TNM-stage on OS, patients with III--IV cancer in the three groups were analyzed separately. Survival analysis was performed on high and low TRIM36 expression subgroups with and without radiotherapy in patients with stage III/IV GC. The OS rate of patients with stage III/IV GC that had high TRIM36 expression was increased in those that received radiotherapy compared with those who did not receive radiotherapy. This suggested that TRIM36 may be involved in radiotherapy sensitivity in GC.

Gene expression in tumor tissues is usually associated with clinicopathological factors ([@b20-ol-0-0-10122]--[@b22-ol-0-0-10122]). The overexpression of programmed death-ligand 1 was beneficial in patients with breast carcinoma that received radiotherapy and the expression status was affected by intrinsic subtypes ([@b20-ol-0-0-10122]). Previous studies have reported that high expression levels of chromosomal maintenance 1 (CRM1) or cyclin dependent kinase 5 (CDK5) in GC lead to increased OS rates when compared with low expression levels. The expression level of CRM1 was associated with lymph node metastasis and the TNM-stage, and CDK5 expression levels were associated with sex and Lauren\'s classification ([@b21-ol-0-0-10122]). In the present study, TRIM36 expression levels were an independent factor, suggesting that TRIM36 may be a radiosensitivity gene signature in GC radiotherapy.

E3 ubiquitin ligases are divided into two major groups: The homologous to the E6-AP carboxyl terminus family and the really interesting new gene finger-containing protein family ([@b25-ol-0-0-10122]). The latter is the larger group and binds to E2 ubiquitin ligase to promote ubiquitination ([@b26-ol-0-0-10122]--[@b28-ol-0-0-10122]). Studies have revealed that E3 ubiquitin ligases may be involved in the occurrence of GC, and that they are highly expressed in malignant gastric tumors ([@b4-ol-0-0-10122],[@b29-ol-0-0-10122]). E3 ubiquitin ligase is an oncogene that is highly expressed in patients with GC with a poor prognosis ([@b29-ol-0-0-10122]). However, studies have shown that E3 ubiquitin ligase may have a tumor suppressor function in GC ([@b30-ol-0-0-10122],[@b31-ol-0-0-10122]) as E3 ubiquitin ligase is often deregulated during the development of GC. The specific mechanism and role of E3 ubiquitin ligase in the treatment of GC requires further study.

The p53 signaling pathway is a central regulator of cell proliferation that directly regulates the transcription of genes involved in the cell cycle and DNA repair ([@b32-ol-0-0-10122]--[@b34-ol-0-0-10122]). The primary mechanism of p53 signaling in the repair of cellular DNA is ubiquitination ([@b35-ol-0-0-10122]). The E3 ubiquitin ligase is a negative regulator of p53 and mainly exerts its effects via degradation of p53 and inhibition of the transcriptional target of p53 ([@b10-ol-0-0-10122],[@b11-ol-0-0-10122]). It can be speculated that high expression of TRIM36 may enhance sensitivity to radiotherapy by inhibiting the p53 signaling pathway via its own unique E3 ubiquitin ligase structure. The extracellular signal-regulated kinase (ERK) signaling pathway regulates cell proliferation, differentiation and survival, and mediates and amplifies signals during tumor invasion and metastasis ([@b36-ol-0-0-10122]). Previous studies have demonstrated that the extracellular signal-regulated kinase (ERK) signaling pathway is associated with tumor radiation resistance ([@b37-ol-0-0-10122],[@b38-ol-0-0-10122]). In addition, previous studies have indicated that TRIM36 serves an inhibitory effect on the ERK signaling pathway in prostate cancer ([@b39-ol-0-0-10122]). Based on these studies, TRIM36 may increase radiosensitivity by inhibiting the ERK signaling pathway in GC.

Radiosensitivity of the tumor is linked to the immune response, and radiation itself is considered to be immunosuppressive ([@b40-ol-0-0-10122],[@b41-ol-0-0-10122]). The TRIM family is involved in immunity and carcinogenesis in cellular processes. TRIM36 may serve an important role in the process of radiation immunity by inducing cancer cells to undergo apoptosis. TRIM proteins have been studied in numerous types of cancer, and TRIM overexpression has been observed in GC. However, the molecular mechanism linking TRIM overexpression and GC pathology remains unclear. A previous study suggested that the TRIM25 gene enhanced cell migration and invasion by activating the transforming growth factor β pathway in GC, and that overexpression of TRIM25 resulted in poor outcomes ([@b42-ol-0-0-10122]). TRIM44 and TRIM59 are also associated with GC, and a high expression was associated with poor outcome ([@b22-ol-0-0-10122],[@b43-ol-0-0-10122]). Previous research has demonstrated that TRIM59 promotes gastric tumorigenesis through suppression of downstream signals of p53 ([@b43-ol-0-0-10122]). The results obtained from these studies suggested that high expression of TRIM resulted in poor GC prognosis. However, the current study revealed that the expression of TRIM36 is not associated with the prognosis of GC; however, high expression may be associated with improved OS rates of patients receiving radiotherapy. Based on the results obtained in the current study, TRIM36 may be associated with the radiosensitivity in GC. However, the biological pathways involved remain to be explored.

The current study has certain limitations. First, a sample size of 371 is relatively small. However, this limitation was partially overcome using a cross-validation strategy to investigate the association between TRIM36 expression and radiosensitivity. Second, TRIM36 is located on chromosome 5q22.3, which frequently contains DNA alterations in tumor ([@b44-ol-0-0-10122]). The mRNA level of TRIM36 may not accurately represent the expression of the TRIM36 gene. Therefore, using the median mRNA expression level of TRIM36 to divide groups could cause a bias. Finally, potential bias could arise from variation in the follow-up information obtained from TCGA due to the retrospective nature of the TCGA cohort.

In conclusion, the current study demonstrated the potential predictive and prognostic value of TRIM36 expression status in a TCGA dataset of patients with GC that received radiotherapy. However, further studies are required to validate the predictive value of this potential biomarker. High TRIM36 expression levels were associated with improved clinical prognosis in patients with GC receiving radiotherapy, possibly through the downregulation of the p53 signaling pathway. The results obtained in the current study provide novel insights into the treatment of GC, any may be particularly useful for clinical trials determining radiation resistance and sensitivity in patients.
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###### 

Clinical characteristics in the test, validation and all patients groups.

                      Test group (n=185)     Validation group (n=186)   All patients (n=371)                                                                                                                               
  ------------------- ---------------------- -------------------------- ---------------------- ------- ---------------------- ------- ---------------------- ------- ---------------------- ------- ---------------------- -------
  Sex                                                                                                                                                                                                                      
    Male              1.578 (0.893--2.787)   0.116                      1.458 (0.755--2.815)   0.260   1.066 (0.679--1.673)   0.780   1.515 (0.873--2.628)   0.140   1.243 (0.882--1.752)   0.214   1.521 (0.999--2.315)   0.051
    Female            1                                                 1                              1                              1                              1                              1                      
  Age (years)                                                                                                                                                                                                              
    \>60              1.420 (0.862--2.338)   0.168                      1.491 (0.797--2.791)   0.210   1.358 (0.793--2.327)   0.265   1.534 (0.769--3.061)   0.224   1.407 (0.979--2.024)   0.065   1.332 (0.849--2.089)   0.212
    ≤60               1                                                 1                              1                              1                              1                              1                      
  Histology                                                                                                                                                                                                                
    MT+DT+ST          0.413 (0.201--0.847)   0.016                      0.461 (0.181--1.171)   0.103   1.768 (0.907--3.447)   0.093   1.659 (0.600--4.524)   0.331   0.878 (0.543--1.417)   0.594   1.057 (0.578--1.932)   0.858
    NOS               0.830 (0.475--1.450)   0.511                      0.978 (0471--2.032)    0.953   1.646 (0.897--3.021)   0.107   1.514 (0.700--3.217)   0.291   1.172 (0.779--1.765)   0.446   1.128 (0.695--1.832)   0.625
    PT+TT             1                                                 1                              1                              1                              1                              1                      
  TNM-stage                                                                                                                                                                                                                
    II                1.482 (0.592--3.713)   0.401                      0.460 (0.111--1.896)   0.282   1.723 (0.634--4.687)   0.286   1.377 (0.283--6.703)   0.690   1.586 (0.807--3.117)   0.181   1.110 (0.349--3.531)   0.859
    III               2.158 (0.896--5.196)   0.086                      0.419 (0.066--2.635)   0.353   2.773 (1.096--7.017)   0.031   2.680 (0.297--24.14)   0.379   2.448 (1.297--4.622)   0.006   0.967 (0.103--8.918)   0.969
    IV                3.390 (1.200--9.575)   0.021                      0.274 (0.037--2.015)   0.203   4.025 (1.372--11.80)   0.011   2.925 (0.145--58.96)   0.484   3.636 (1.729--7.646)   0.001   1.215 (0.067--22.05)   0.895
    I                 1                                                 1                              1                              1                              1                              1                      
  T-stage                                                                                                                                                                                                                  
    T3                2.154 (1.105--4.200)   0.024                      2.808 (1.011--7.796)   0.047   1.467 (0.813--2.647)   0.203   0.546 (0.204--1.465)   0.230   1.756 (1.133--2.273)   0.012   1.559 (0.778--3.128)   0.210
    T4                2.413 (1.147--5.074)   0.020                      3.052 (0.935--9.956)   0.064   1.574 (0.635--2.937)   0.154   0.551 (0.182--1.668)   0.292   1.917 (1.192--3.083)   0.007   1.756 (0.801--3.847)   0.159
    T1-T2             1                                                 1                              1                              1                              1                              1                      
  N-stage                                                                                                                                                                                                                  
    N1                1.562(0.834--2.926)    0.164                      2.853 (1.088--7.478)   0.033   1.900 (0.945--3.823)   0.072   1.078 (0.304--3.817)   0.906   1.694 (1.063--2.697)   0.027   1.635 (0.775--3.452)   0.197
    N2                1.051 (0.481--2.298)   0.900                      1.580 (0.433--5.769)   0.488   2.418 (1.163--5.025)   0.017   1.295 (0.284--5.902)   0.738   1.640 (0.975--2.758)   0.062   1.908 (0.738--4.926)   0.182
    N3                2.421 (1.266--4.629)   0.008                      3.985 (1.088--14.59)   0.036   3.039 (1.508--6.125)   0.002   1.358 (0.307--5.988)   0.686   2.652 (1.654--4.250)   0.001   2.777 (1.074--7.179)   0.035
    N0                1                                                 1                              1                              1                              1                              1                      
  M-stage                                                                                                                                                                                                                  
    M1                2.563 (1.223--5.880)   0.014                      0.774 (0.183--3.269)   0.728   1.315 (0.692--2.499)   0.403   0.791 (0.095--6.575)   0.829   1.836 (0.991--3.401)   0.054   0.403 (0.123--1.316)   0.132
    M0                1                                                 1                              1                              1                              1                              1                      
  Tumor-grade                                                                                                                                                                                                              
    G3                1.168 (0.713--1.916)   0.536                      1.212 (0.621--2.363)   0.573   1.702 (1.059--2.738)   0.028   1.524 (0.773--3.000)   0.223   1.344 (1.136--1.591)   0.001   1.090 (0.490--2.420)   0.833
    G1-G2             1                                                 1                              1                              1                              1                              1                      
  Residual                                                                                                                                                                                                                 
    R1                3.091 (1.318--7.251)   0.009                      4.843 (1.543--15.17)   0.007   1.000 (0.311--7.251)   0.991   0.878 (0.234--3.291)   0.848   1.786 (0.902--3.539)   0.096   2.017 (0.934--4.355)   0.074
    R2                10.27 (5.185--20.34)   0.001                      8.025 (2.801--22.99)   0.001   3.727 (1.695--8.196)   0.001   3.491 (0.721--16.89)   0.120   6.180 (3.096--12.34)   0.001   4.517 (1.659--12.29)   0.003
    R0                1                                                 1                              1                              1                              1                              1                      
  Targeted therapy                                                                                                                                                                                                         
    Yes               0.545 (0.335--0.886)   0.014                      0.557 (0.279--1.112)   0.097   0.810 (0.517--1.271)   0.361   1.017 (0.520--1.989)   0.959   0.672 (0.484--0.933)   0.018   0.863 (0.547--1.362)   0.527
    No                1                                                 1                              1                              1                              1                              1                      
  Radiotherapy                                                                                                                                                                                                             
    Yes               0.377 (0.186--0.765)   0.007                      0.541 (0.212--1.324)   0.178   0.429 (0.230--0.810)   0.008   0.401 (0.163--0.988)   0.047   0.405 (0.253--0.646)   0.001   0.408 (0.217--0.765)   0.005
    No                1                                                 1                              1                              1                              1                              1                      
  TRIM36 expression                                                                                                                                                                                                        
    High              0.815 (0.512--1.299)   0.390                      1.234 (0.691--2.204)   0.476   0.753 (0.468--1.213)   0.244   0.939 (0.520--1.696)   0.837   0.761 (0.553--1.048)   0.095   0.828 (0.565--1.215)   0.335
    Low               1                                                 1                              1                              1                              1                              1                      

HR, hazard ratio; ST, signet ring type; DT, diffuse type; MT, mucinous type; PT, papillary type; TT, tubular type; TRIM36, tripartite motif containing 36; R, residual; T, tumor; G, grade; M, metastasis; N, node; NOS, not otherwise specified; TNM, Tumor-Node-Metastasis.

###### 

Association between TRIM36 expression and clinicopathological features of patients with gastric cancer.

                TRIM36 expression status                 
  ------------- -------------------------- ----- ------- -------
  Sex                                            0.032   0.858
    Female      64                         66            
    Male        121                        120           
  Age (years)                                    0.166   0.784
    ≤60         59                         56            
    \>60        124                        129           
  Histology                                              
    PT+TT       40                         42    0.101   0.951
    DT+ST+MT    40                         47            
    NOS         82                         94            
  TNM-stage                                      0.101   0.750
    I--II       87                         84            
    III--IV     91                         94            
  T-stage                                        0.103   0.748
    T1-T2       51                         48            
    T3-T4       133                        135           
  N-stage                                        0.940   0.332
    N0-N1       113                        104           
    N2-N3       67                         76            
  M-stage                                        0.125   0.723
    M0          170                        169           
    M1          15                         17            
  Tumor grade                                    0.057   0.811
    G1-G2       72                         69            
    G3          110                        111           
  Residual                                       0.001   0.972
    R0          156                        154           
    R1-R2       17                         17            

PT, papillary type; TT, tubular type; ST, signet ring type; DT, diffuse type; MT, mucinous type; NOS, not otherwise specified; T, tumor; N, node; M, metastasis; G, grade; R, residual; TRIM36, tripartite motif containing 36; TNM, Tumor-Node-Metastais.

###### 

Association between RT and overall survival rate in tripartite motif containing 36 high and low expression subgroups.

  A, Test group                                                                                                                                                 
  ------------------------- ------------------------ ---------------------------------------- ------------------------------------------ ---------------------- -------------
  High                      92                       0.062 (0.008--0.462)                     0.007                                      0.095 (0.012--0.748)   0.025
  Low                       93                       0.902 (0.411--1.981)                     0.797                                      0.786 (0.283--2.183)   0.643
                                                                                                                                                                
  **B, Validation group**                                                                                                                                       
                                                                                                                                                                
                                                     **Univariate analysis (RT vs. no RT)**   **Multivariate analysis (RT vs. no RT)**                          
                                                                                                                                                                
  **Expression level**      **Number of patients**   **HR**                                   **P-value**                                **HR**                 **P-value**
                                                                                                                                                                
  High                      96                       0.190 (0.067--0.540)                     0.002                                      0.075 (0.020--0.276)   \<0.001
  Low                       90                       1.035 (0.467--2.294)                     0.931                                      0.804 (0.304--2.127)   0.661
                                                                                                                                                                
  **C, All patients**                                                                                                                                           
                                                                                                                                                                
                                                     **Univariate analysis (RT vs. no RT)**   **Multivariate analysis (RT vs. no RT)**                          
                                                                                                                                                                
  **Expression level**      **Number of patients**   **HR**                                   **P-value**                                **HR**                 **P-value**
                                                                                                                                                                
  High                      188                      0.133 (0.053--0.334)                     \<0.001                                    0.094 (0.030--0.296)   \<0.001
  Low                       183                      0.959 (0.549--1.674)                     0.884                                      1.079 (0.421--1.725)   0.658

RT, radiation therapy; HR, hazard ratio.

[^1]: Contributed equally
